Trials / Unknown
UnknownNCT04973735
A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects
A Phase I, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of LY-CovMab Injection in Chinese Healthy Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Luye Pharma Group Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A single center, randomized, doubled-blind, placebo-control and single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of LY-CovMab Injection in Chinese healthy subjects.
Detailed description
A single center, randomized, doubled-blind, placebo-control and single ascending dose phase I study: Primary objective: to evaluate the safety and tolerability of a single dose of LY-CovMab Injection in Chinese healthy subjects. Secondary objective: to evaluate the pharmacokinetics (PK) and immunogenicity of a single dose of LY-CovMab injection in Chinese healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY-CovMab | single IV infusion |
Timeline
- Start date
- 2020-11-10
- Primary completion
- 2021-05-01
- Completion
- 2021-07-31
- First posted
- 2021-07-22
- Last updated
- 2021-07-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04973735. Inclusion in this directory is not an endorsement.